Additionally, in IBD patients receiving anti-TNF-α therapy, clinical monitoring protocols should be individualized, emphasizing close surveillance of respiratory symptoms during the initial treatment phase, especially within the first 6–12 months following treatment initiation [28]. This evidence concerns the gene TNF and inflammatory bowel disease.